NEW DELHI: Shares of Dr. Reddy's Laboratories traded 1.06 per cent up in Thursday 's trade at 09:39AM (IST).
Around 194775 shares changed hands on the counter. The stock opened at Rs 3806.4 and touched an intraday high and low of Rs 3865.0 and Rs 3780.0 , respectively, in the session so far.
The stock quoted a 52-week high of Rs 3881.7 and a 52-week low of Rs 1872.95 .
The company is in the early stages of creating a generic copy of remdesivir, the experimental drug developed by Gilead that’s said to have improved the condition of critically ill Covid-19 patients in a multicountry trial.
Financials
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 63211.03 Crore) operating in Pharmaceuticals sector.
For the quarter ended 31-12-2019, the company reported a Consolidated sales of Rs 4383.80 Crore, down -8.69 % from last quarter Sales of Rs 4800.80 Crore and up 15.79 % from last year same quarter Sales of Rs 3786.10 Crore. The Company reported net profit after tax of Rs -556.00 Crore in latest quarter.
Dr. Reddy's Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 10466.70 Crore to Sales Value (98.50 % of Total Sales), Licence Fees which contributed Rs 55.90 Crore to Sales Value (0.52 % of Total Sales), Service Income which contributed Rs 50.30 Crore to Sales Value (0.47 % of Total Sales), Spent Chemicals which contributed Rs 35.60 Crore to Sales Value (0.33 % of Total Sales), Scrap which contributed Rs 16.10 Crore to Sales Value (0.15 % of Total Sales) and Other Operating Revenue which contributed Rs .90 Crore to Sales Value (0.00 % of Total Sales)for the year ending 31-Mar-2019.
Promoter holding
Promoters held 26.755949 per cent stake in the company as of quarter ended 31st Dec 2019 .
Valuation ratio
It quoted a price-to-earnings ratio of 37.21 and price to book value of 4.51 .